Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension Arena Pharmaceuticals, Inc kjøpe levitra på nett . announced today results from a Phase 1 medical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is supposed for the treatment of pulmonary arterial hypertension, or PAH. The randomized, double-blind and placebo-controlled trial evaluated the safety, pharmacokinetics and tolerability of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single dosages of APD811. APD811 was quickly absorbed and demonstrated dose-proportional pharmacokinetic publicity over the tested dosage range.


Argos Soditic-managed funds announce acquisition of Cisbio Bioassays The funds managed by Argos Soditic announce the acquisition, together with the management, of Cisbio Bioassays. This cutting-edge biotechnology company may be the leader in the field of products and services for individual in vitro diagnostics and pharmaceutical analysis. Through this Administration Buy-Out procedure Cisbio Bioassays turns into independent, using its spin-off departure from the Belgian group IBA. The acquisition represents a significant step forward in the annals of Cisbio Bioassays. The firm's 25 years of experience have trained with an established position as a significant player in the world of diagnostics and biotechnologies. The arrival of Argos Soditic opens up prospects for strategic growth, and can enable the business to strengthen its market positions.